Congress Opening & Welcome
Piercarlo Sarzi-Puttini, Italy | Congress Co-Chair
Session 1: Where are we going?
Fibromyalgia: Year in Review
Chronic Pain: Year in Review
Classification and epidemiology of chronic pain – where are we going?
A closer look at the concept of “Nociplastic pain”. What is it good for?
Session 2: Focus on pathogenesis
Passive Transfer of Fibromyalgia
Genetics, Genomics and epigenetics in fibromyalgia and chronic pain
Fatigue in fibromyalgia: a brain-muscle mismatch
Fibromyalgia – an autoimmune dysautonomic syndrome like the Post COVID19 syndrome
LIVE Panel Discussion/Q&A 1
Oral Presentations of Selected Abstracts
Somatic and Non-Somatic Sensitivity in Men and Women with Fibromyalgia: Are men with fibromyalgia overlooked?
Fibromyalgia and chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS): overlapping conditions for men
Session 3: Other Debatable Pain Mechanisms
Is there such a thing as "Regional Fibromyalgia"?
Metabolomics, Proteomics and all the other Omics: Will we ever have a reliable biomarker for fibromyalgia?
Placebo demystified: mechanisms, utilization, and pitfalls
What is the proper model to evaluate treatment response in chronic pain models?
Session 4: Clinical Issues
Sexual issues in fibromyalgia and chronic pain
Suicidal Behavior in Fibromyalgia Patients: Rates and Determinants of Suicide Ideation, Risk, Suicide, and Suicidal Attempts—A Systematic Review of the Literature and Meta-Analysis of Over 390,000 Fibromyalgia Patients
A heavy problem: the association of fibromyalgia and obesity
Session 5: Registries, Disability and Prevention
Disability due to Fibromyalgia Syndrome recognized by Israeli law after struggle led by ASAF Association
Long term story: data from registries?
Any chance of prevention?
LIVE Panel Discussion/Q&A 2
End of Day One
Congress Welcome - Day 2
Jacob Ablin, Israel | Congress Co-Chair
Session 6: Primary or Concomitant?
Long – COVID, chronic fatigue and everything in between – what have we learned and where may it impact on fibromyalgia
Why patients affected by rheumatoid arthritis or other inflammatory articular syndromes may develop a concomitant fibromyalgia?
Small fiber neuropathy: is still relevant?
Session 7: An Eye to the Pharmacological Opportunities
L-acetyl carnitine : What are we looking for?
Do biologics work in chronic pain?
Jak inhibitors may modulate pain and fatigue?
Should we treat fibromyalgia with a combined pharmacological approach
LIVE Panel Discussion/Q&A 3
Oral Presentations of Selected Abstracts II
SLEEP STUDY FINDINGS IN FIBROMYALGIA AND OBESITY
PREVALENCE OF FIBROMYALGIA SYNDROME IN A COHORT OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE
Validity of the Central Sensitization Inventory compared with traditional measures of disease severity in fibromyalgia
The effect of pain catastrophizing subdomains on disease severity levels and presenteeism-related productivity loss in female workers with fibromyalgia
Session 8: Non-pharmacological Offer
Mind and body treatment; do we have new data?
Oxygen-Ozone Therapy in Fibromyalgia
Session 9: Do all the drugs work in chronic pain?
Precision medicine approach to chronic pain
Non steroidal anti-inflammatory drugs: why not?
Cannabinoids: Focus on CBD
The role of glucocorticoids on chronic inflammatory pain
LIVE Panel Discussion/Q&A 4
Session 10: The Patients Associations: Do we need them?
The Brazilian Experience
Introducing the European Network of Associations
Why patients’ associations are so important both for doctors and patients?
ENFA: management of Fibromyalgia in Europe
ENFA project for an Aknowledgement's Resolution by EU Commission
LIVE Panel Discussion/Q&A 5 & Congress Closing
End of Congress